Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.9K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.9K
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

6
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
6
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

5
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
5
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cortical GABAergic dysfunction underlying abnormal hand movements in ARX mutation.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2019
Same author

Gelastic Cataplexy in Niemann Pick Type C.

Movement disorders clinical practice·2019
Same author

The Interaction Between Neuroinflammation and β-Amyloid in Cognitive Decline in Parkinson's Disease.

Molecular neurobiology·2019
Same author

Tongue Protrusion Dystonia in Pantothenate Kinase-Associated Neurodegeneration.

Pediatric neurology·2019
Same author

Amantadine for Gait Dysfunction in Pantothenate Kinase-Associated Neurodegeneration.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2019
Same author

Deep brain stimulation in status dystonicus caused by anti-NMDA receptor encephalitis.

Parkinsonism & related disorders·2019

Related Experiment Video

Updated: Apr 19, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.7K

Behavioral effects of levodopa.

Isabelle Beaulieu-Boire1, Anthony E Lang

  • 1Morton & Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada; Division of Neurology, Department of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, Canada.

Movement Disorders : Official Journal of the Movement Disorder Society
|December 11, 2014
PubMed
Summary
This summary is machine-generated.

Levodopa-induced behavioral changes in Parkinson's disease are common and underdiagnosed. New strategies are emerging to manage these neuropsychiatric symptoms while treating motor function.

Keywords:
Behavioral effectsDopamine dysregulationImpulse controlLevodopaManiaParkison's DiseasePsychosisPunding

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.7K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

19.3K

Related Experiment Videos

Last Updated: Apr 19, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.7K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.7K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

19.3K

Area of Science:

  • Neurology
  • Neuroscience
  • Psychiatry

Background:

  • Levodopa-induced behavioral changes are increasingly recognized in Parkinson's disease (PD) patients.
  • These changes encompass a wide range of neuropsychiatric symptoms, including psychosis, impulse control disorders, and mood disturbances.

Purpose of the Study:

  • To review the spectrum of levodopa-induced behavioral changes in PD.
  • To discuss current understanding of their underlying mechanisms.
  • To explore emerging management strategies.

Main Methods:

  • Literature review of recent studies on levodopa-induced behavioral changes in Parkinson's disease.
  • Analysis of imaging and pathological data.
  • Evaluation of current and novel therapeutic approaches.

Main Results:

  • Levodopa-induced behavioral changes, including psychosis and impulse control disorders, are prevalent but often underdiagnosed.
  • Mechanisms are still being elucidated, but neuroimaging and pathology offer insights.
  • Effective management is challenging due to the need to balance motor symptom control with behavioral side effects.

Conclusions:

  • Despite challenges, understanding the mechanisms of levodopa-induced behavioral changes is improving.
  • Novel dopaminergic delivery systems, deep brain stimulation, and non-dopaminergic agents offer potential for better management.
  • These approaches may allow for effective parkinsonism treatment with reduced risk of behavioral complications.